SPC25 is a critical component of the NDC80 kinetochore complex essential for proper chromosome 2 and spindle checkpoint function 12. It organizes stable microtubule binding sites at the kinetochore's outer plate and synergistically enhances the SKA1 complex's microtubule affinity, enabling tracking of depolymerizing microtubules 3. Beyond its canonical mitotic role, SPC25 has emerged as a significant oncogenic driver across multiple cancer types. In epithelial ovarian cancer, SPC25 functions as a scaffolding protein orchestrating an SPC25/RIOK1/MYH9 complex that promotes cancer stem cell phenotypes and platinum resistance through Wnt/β-catenin pathway activation 4. In lung adenocarcinoma, SPC25 upregulation associates with poor prognosis and promotes glycolysis, cell cycle progression, and ferroptosis dysregulation 56. Similar oncogenic roles occur in breast cancer and hepatocellular carcinoma, where elevated SPC25 correlates with reduced survival and accelerated cell cycle progression 78. In lung cancer with idiopathic pulmonary fibrosis, SPC25 mutations increase expression and promote epithelial-to-mesenchymal transition 9. Recent evidence shows berberine suppresses non-small cell lung cancer through SPC25/NUF2 axis inhibition 10. These findings establish SPC25 as a promising therapeutic target and prognostic biomarker across multiple malignancies.